India APIs Incentive Scheme: Will It Galvanize Local Firms, Bridle The Dragon?
Aims To Improve Self-Sufficiency
Executive Summary
India shapes new production-linked incentives scheme for critical APIs to ensure self-reliance and cut massive dependence on imports from China, but much will depend on actual implementation, including timely clearances. Pharma will also need to 'walk the talk' alongside.
You may also be interested in...
Supply Chain Crunch Meets Olympics Shutdown: China, India Drug Makers Embrace For Perfect Storm
To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile global pharma active ingredient supply chain. The emergence of the Omicron coronavirus variant is just adding to the complexities.
Merck & Co, Indian Firms On Tackling Supply Chain Risks And A Hijack
Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.
Hot Space: PE Advent Snaps Up Second API Manufacturer In India
Private equity investor Advent has acquired API maker ZCL Chemicals in India, its second transaction in a segment seeing rising interest as pharma de-risks sourcing for key ingredients post COVID-19-related turbulence.